CXCL16 and cancer: For the comparison of all UCa patients vs. those with other cancers and no cancer at all, we obtained an AUC of 0.77 (95% CI 0.71–0.83; Fig. 4C) for CXCL16 and an AUC of 0.77 (95% CI 0.71–0.84; Fig. 4D) for TGFBI.